Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling.

Saved in:
Bibliographic Details
Title: Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling.
Authors: Bertuglia G; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy., Seneca E; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Corbett T; Department of Haematology, University Hospitals Sussex NHS Foundation Trust, Worthing West Sussex, United Kingdom., Croft J; Department of Haematology, Epsom & St Helier University Hospitals, Surrey, United Kingdom., Kaczmarek P; Department of Haematology, East Surrey Hospital, Redhill, United Kingdom., Ellis L; Department of Haematology, Croydon University Hospital, London, United Kingdom., Neoh C; Department of Haematology, Royal Surrey NHS Foundation Trust, Guildford, United Kingdom., Renaudon-Smith E; Department of Haematology, Frimley Park Hospital, Frimley Surrey, United Kingdom., Vanhinsbergh L; Department of Haematology, St Peter's Hospital, Chertsey Surrey, United Kingdom., Lindsay J; Department of Haematology, East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom., Bonetto S; Department of Haematology, Kingston Hospital NHS Foundation Trust, London, United Kingdom., Kristinsson SY; Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Haematology, Landspítali - The National University Hospital of Iceland, Reykjavik, Iceland., Spence D; Department of Haematology, Turks and Caicos Islands Hospital, Turks and Caicos Islands, Providenciales., Pratt G; Department of Haematology, Turks and Caicos Islands Hospital, University Hospitals Birmingham NHS Foundation Trust, Turks and Caicos Islands, Providenciales, Birmingham, United Kingdom., Jackson G; Department of Haematology, Newcastle University, Newcastle, United Kingdom., Ethell M; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Nicholson E; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Messiou C; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Brown T; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Conneely L; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Thornton T; Haematologic Malignancies Diagnostic Service and Genomics Laboratory Hub, The Royal Marsden Hospital, London, United Kingdom., Fuller L; Haematologic Malignancies Diagnostic Service and Genomics Laboratory Hub, The Royal Marsden Hospital, London, United Kingdom., Petrizan MV; Haematologic Malignancies Diagnostic Service and Genomics Laboratory Hub, The Royal Marsden Hospital, London, United Kingdom., Dunlop A; Haematologic Malignancies Diagnostic Service and Genomics Laboratory Hub, The Royal Marsden Hospital, London, United Kingdom., Smith K; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Gay F; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy., Pawlyn C; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Boyd KD; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Kaiser MF; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom. Electronic address: martin.kaiser@icr.ac.uk.
Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2026 Feb; Vol. 26 (2), pp. e188-e200.e5. Date of Electronic Publication: 2025 Nov 10.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2152-2669
DOI:10.1016/j.clml.2025.11.003